Probiotics to prevent necrotizing enterocolitis: Too cheap and easy?

Paediatrics and Child Health (Canada)

Volumn 19, Issue 7, 2014, Pages 351-352

  Taylor, Richard S ^a  

^a VICTORIA GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; PROBIOTIC AGENT;

CYSTIC FIBROSIS; DEVELOPED COUNTRY; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE UNIT; LACTOBACILLUS RHAMNOSUS; NECROTIZING ENTEROCOLITIS; NEONATOLOGIST; NOTE; PREMATURITY; SACCHAROMYCES BOULARDII;

EID: 84907007680     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/19.7.351     Document Type: Note

References (18)

1. AlFaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. http://summaries.cochrane.org/CD005496/probiotics-for-prevention-of-necrotizingenterocolitis-in-preterm-infants. (Accessed February 2014).
2. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
3. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
4. Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA. Palivizumab vaccine for prevention of respiratory syncytial virus infection in children with cystic fibrosis. http://summaries.cochrane.org/CD007743/palivizumab-vaccine-for-prevention-of-respiratorysyncytial- virus-infection-in-children-with-cystic-fibrosis. (Accessed February 2014).
5. Ofek Shlomai N, Deshpande G, Rao S, Patole S. Probiotics for preterm neonates: What will it take to change clinical practice? Neonatology 2014;105:64-70.
6. Prais D, Danino D, Schonfeld T, Amir J. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis. Chest 2005;128:2765-71.
7. Rees CM, Pierro A, Eaton S. Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis. Arch Dis Child Fetal Neonatal Ed 2007;92:F193-F198.
8. Isayama T, Lee SK, Mori R, et al. Comparison of mortality and morbidity of very low birth weight infants between Canada and Japan. Pediatrics 2012;130:e957-e965.
9. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
10. Janvier A, Lantos J, Barrington K. The politics of probiotics: Probiotics, necrotizing enterocolitis and the ethics of neonatal research. Acta Pædiatrica 2013;102:116-8.
11. Bisquera JA, Cooper TR, Berseth CL. Impact of necrotizing enterocolitis on length of stay and hospital charges in very low birth weight infants. Pediatrics 2002;109:423-8.
12. Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it? Arch Dis Child Fetal Neonatal Ed 2005;90:F286-F289.
13. Janvier A, Malo J, Barrington KM. Cohort study of probiotics in a North American neonatal intensive care unit. J Pediatr 2014;164:980-5.
14. Tarnow-Mordi W, Soll R. Probiotic supplementation in preterm infants: It is time to change practice. J Pediatr 2014;164:959-60.
15. Serce O, Benzer D, Gursoy T, Karatekin G, Ovali F. Efficacy of Sacharomyces boulardii on necrotizing enterocolitis or sepsis in very low birth weight infants: A randomized controlled trial. Early Hum Dev 2013;89;1033-6.
16. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: A comprehensive review. Clin Infect Dis 2005;41:1559-68.
17. Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli F. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. Biol Neonate 2002;82:103-8.
18. Deshpande GC, Rao SC, Keil AD Patole SK. Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med 2011;9:92.